Newswire (Published: Monday, September 24, 2018, Received: Thursday, September 20, 2018, 12:28:10 PM CDT)

Word Count: 523

Studies from Cancer Institute in the Area of Prostate Cancer Reported (The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting from Durham, North Carolina, by NewsRx journalists, research stated, "Until 2015, androgen deprivation therapy (ADT) alone was the standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). In 2015, the CHAARTED and STAMPEDE-Docetaxel studies demonstrated marked survival benefit with the addition of docetaxel to ADT in the mHSPC setting, leading to a change in the standard-of-care for mHSPC."

The news correspondents obtained a quote from the research from Cancer Institute, "The recent LATITUDE and STAMPEDE-Abiraterone trials showed similar substantial improvement in survival with the addition of abiraterone plus prednisone to ADT in this space. We conducted a review of the randomized phase III studies that have investigated either the addition of docetaxel or abiraterone to ADT in patients with mHSPC. We describe the study designs, key eligibility criteria, and key results for the CHAARTED, STAMPEDE-Docetaxel, GETUG-AFU 15, LATITUDE, and STAMPEDE-Abiraterone clinical trials. We compare the data for abiraterone/prednisone plus ADT in mHSPC with the evidence for docetaxel plus ADT in these patients. Finally, we discuss several factors that should be considered when choosing between docetaxel/ADT or abiraterone/prednisone/ADT in mHSPC. The management of mHSPC is evolving."

According to the news reporters, the research concluded: "Abiraterone plus prednisone in addition to ADT has emerged as an alternative standard-of-care to docetaxel plus ADT, and ongoing trials should clarify whether combination vs. sequential approaches with AR-targeting agents and taxane chemotherapy are preferred for initial management in the hormone-sensitive setting."

For more information on this research see: The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer and Prostatic Diseases, 2018;21(3):306-318. Prostate Cancer and Prostatic Diseases can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group -; Prostate Cancer and Prostatic Diseases -

Our news journalists report that additional information may be obtained by contacting M. McNamara, Duke Prostate & Urol Canc Center, Canc Inst, Durham, NC 27710, United States. Additional authors for this research include C. Sweeney, E.S. Antonarakis and A.J. Armstrong (see also Oncology - Prostate Cancer).

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Durham, North Carolina, United States, North and Central America, Adrenal Cortical Steroids, Health and Medicine, Drugs and Therapies, Prostatic Neoplasms, Prednisone Therapy, Mitotic Inhibitors, Docetaxel Therapy, Pharmaceuticals, Glucocorticoids, Antineoplastics, Prostate Cancer, Androgens, Hormones, Oncology, Cancer Institute.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC


Central America
North America
Northern Europe
United Kingdom
United States
North Carolina


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies
            Medicinal Drugs